目的:探討莫西沙星注射液應(yīng)用在中重度急性腹腔感染治療中的臨床療效與安全性。方法:共納入31 例患者,隨機(jī)分為羅氏芬加甲硝唑治療組(對(duì)照),羅氏芬2 g,每日1次,甲硝唑0.5 g,每日2次;莫西沙星治療組,莫西沙星400mg,每日1次,均為靜脈滴注,療程為7~14 天。結(jié)果:兩組的痊愈率分別為80 ％和81.25 ％,有效率分別為86.67 ％和87.5 ％,細(xì)菌清除率分別為91.67%與90%。組間比較差異均無(wú)統(tǒng)計(jì)學(xué)意義。兩組的不良反應(yīng)發(fā)生分別為2／15和 1／16,主要表現(xiàn)為局部刺激及轉(zhuǎn)氨酶升高等。結(jié)論:莫西沙星注射液治療中重度腹腔細(xì)菌感染療效確切,安全性好。
引用本文： 李雪梅,黃立平. 莫西沙星治療腹腔內(nèi)感染的藥物學(xué)研究. 華西醫(yī)學(xué), 2009, 24(7): 1856-1858. doi: 復(fù)制
| 1. | MIRAVITLLES M, ANZUETO A. Moxifloxacin: a respiratory fluoroquinolone [J]. Expert Opin Pharmacother, 2008, 9(10):1755-1772. |
| 2. | SIMOENS S, DECRAMER M. A pharmacoeconomic review of the management of respiratory tract infections with moxifloxacin [J]. Expert Opin Pharmacother, 2008, 9(10):1735-1744. |
| 3. | RINK AD, STASS H, DELESEN H, KUBITZA D, VESTWEBER KH. Pharmacokinetics and tissue penetration of moxifloxacin in intervention therapy for intraabdominal abscess [J]. Clin Drug Investig, 2008, 28(2):71-79. |
- 1. MIRAVITLLES M, ANZUETO A. Moxifloxacin: a respiratory fluoroquinolone [J]. Expert Opin Pharmacother, 2008, 9(10):1755-1772.
- 2. SIMOENS S, DECRAMER M. A pharmacoeconomic review of the management of respiratory tract infections with moxifloxacin [J]. Expert Opin Pharmacother, 2008, 9(10):1735-1744.
- 3. RINK AD, STASS H, DELESEN H, KUBITZA D, VESTWEBER KH. Pharmacokinetics and tissue penetration of moxifloxacin in intervention therapy for intraabdominal abscess [J]. Clin Drug Investig, 2008, 28(2):71-79.